These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10547401)

  • 1. Re: Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.
    Castagnetta LA; Carruba G
    J Natl Cancer Inst; 1999 Nov; 91(21):1893-4. PubMed ID: 10547401
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.
    Ursin G; London S; Stanczyk FZ; Gentzschein E; Paganini-Hill A; Ross RK; Pike MC
    J Natl Cancer Inst; 1999 Jun; 91(12):1067-72. PubMed ID: 10379970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer.
    Ursin G; London S; Stanczyk FZ; Gentzschein E; Paganini-Hill A; Ross RK; Pike MC
    Environ Health Perspect; 1997 Apr; 105 Suppl 3(Suppl 3):601-5. PubMed ID: 9168002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.
    Muti P; Bradlow HL; Micheli A; Krogh V; Freudenheim JL; Schünemann HJ; Stanulla M; Yang J; Sepkovic DW; Trevisan M; Berrino F
    Epidemiology; 2000 Nov; 11(6):635-40. PubMed ID: 11055622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women.
    Ursin G; London S; Yang D; Tseng CC; Pike MC; Bernstein L; Stanczyk FZ; Gentzschein E
    Breast Cancer Res Treat; 2002 Mar; 72(2):139-43. PubMed ID: 12038704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary estrogen metabolites and breast cancer: a case-control study.
    Kabat GC; Chang CJ; Sparano JA; Sepkovie DW; Hu XP; Khalil A; Rosenblatt R; Bradlow HL
    Cancer Epidemiol Biomarkers Prev; 1997 Jul; 6(7):505-9. PubMed ID: 9232337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies.
    Ruan X; Seeger H; Wallwiener D; Huober J; Mueck AO
    Arch Gynecol Obstet; 2015 May; 291(5):1141-6. PubMed ID: 25318606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer.
    Alvarez-Vasquez RB; Axelrod D; Frenkel K; Newman MC; Sepkovic DW; Bradlow HL; Zumoff B
    Horm Metab Res; 2003 Jun; 35(6):358-61. PubMed ID: 12920658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones.
    Lu LJ; Cree M; Josyula S; Nagamani M; Grady JJ; Anderson KE
    Cancer Res; 2000 Mar; 60(5):1299-305. PubMed ID: 10728690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women.
    Fowke JH; Longcope C; Hebert JR
    Cancer Epidemiol Biomarkers Prev; 2000 Aug; 9(8):773-9. PubMed ID: 10952093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
    Ziegler RG; Rossi SC; Fears TR; Bradlow HL; Adlercreutz H; Sepkovic D; Kiuru P; Wahala K; Vaught JB; Donaldson JL; Falk RT; Fillmore CM; Siiteri PK; Hoover RN; Gail MH
    Environ Health Perspect; 1997 Apr; 105 Suppl 3(Suppl 3):607-14. PubMed ID: 9168003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study.
    Wellejus A; Olsen A; Tjonneland A; Thomsen BL; Overvad K; Loft S
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2137-42. PubMed ID: 16172222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new ELISA kit for measuring urinary 2-hydroxyestrone, 16alpha-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid.
    Falk RT; Rossi SC; Fears TR; Sepkovic DW; Migella A; Adlercreutz H; Donaldson J; Bradlow HL; Ziegler RG
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):81-7. PubMed ID: 10667467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women.
    Lippert TH; Seeger H; Mueck AO
    Horm Metab Res; 1998 Sep; 30(9):598-600. PubMed ID: 9808331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Estrogen-dependent neoplasia - what is the significance of estradiol metabolites].
    Mueck AO; Seeger H; Lippert TH
    Zentralbl Gynakol; 2003 Nov; 125(11):458-66. PubMed ID: 14634875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of 2-hydroxyestrone /16α-hydroxyestrone ratio in urine of Mexican women as a risk indicator for breast cancer and its relationship with other risk factors].
    Godínez Martínez EY; Santillán Ballesteros R; Lemus Bravo AE; Sámano R; Tolentino Dolores M; Rodríguez Ventura AL; Juárez González AR
    Nutr Hosp; 2014 Oct; 31(2):835-40. PubMed ID: 25617571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Within-person variability of the ratios of urinary 2-hydroxyestrone to 16alpha-hydroxyestrone in Caucasian women.
    Chen Z; Zheng W; Dunning LM; Anderson KG; Parrish RS; Holtzman JL
    Steroids; 1999 Dec; 64(12):856-9. PubMed ID: 10576221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: "A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer".
    Bradlow HL; Kabat GC
    Environ Health Perspect; 1998 Mar; 106(3):A126-7. PubMed ID: 10408943
    [No Abstract]   [Full Text] [Related]  

  • 19. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer.
    Dalessandri KM; Firestone GL; Fitch MD; Bradlow HL; Bjeldanes LF
    Nutr Cancer; 2004; 50(2):161-7. PubMed ID: 15623462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection.
    Fowke JH; Qi D; Bradlow HL; Shu XO; Gao YT; Cheng JR; Jin F; Zheng W
    Steroids; 2003 Jan; 68(1):65-72. PubMed ID: 12475724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.